(Q33342814)

26 July 2017

title

Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia (English)

1 reference

heparin-induced thrombocytopenia

26 July 2017

1 reference

1 reference

1 reference

1 reference

1 reference

Jeanine M Walenga

1

1 reference

26 July 2017

Sarfraz Ahmad

2

1 reference

26 July 2017

Debra Hoppensteadt

3

1 reference

26 July 2017

Omer Iqbal

4

1 reference

26 July 2017

Marcie J Hursting

5

1 reference

26 July 2017

Bruce E Lewis

6

1 reference

26 July 2017

publication date

1 March 2002

1 reference

26 July 2017

1 reference

26 July 2017

volume

105

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

401-405

1 reference

A 14-year study of heparin-induced thrombocytopenia

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

Heparin-Induced Thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

Re-exposure to recombinant (r)-hirudin in antihirudin antibody-positive patients with a history of heparin-induced thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

Argatroban During Percutaneous Transluminal Coronary Angioplasty: Results of a Dose-Verification Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

Effect of Thrombin Inhibition on Patients with Peripheral Arterial Obstructive Disease: A Multicenter Clinical Trial of Argatroban

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

Purification of IgG from serum with caprylic acid and ammonium sulphate precipitation is not superior to ammonium sulphate precipitation alone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900049-X

7 January 2021

10.1016/S0049-3848(02)00049-X

Identifiers

DOI

1 reference

26 July 2017

1 reference